001038463 001__ 1038463
001038463 005__ 20250203124508.0
001038463 0247_ $$2doi$$a10.1001/jamapediatrics.2024.0304
001038463 0247_ $$2ISSN$$a2168-6203
001038463 0247_ $$2ISSN$$a0002-922X
001038463 0247_ $$2ISSN$$a0096-6916
001038463 0247_ $$2ISSN$$a0096-8994
001038463 0247_ $$2ISSN$$a1072-4710
001038463 0247_ $$2ISSN$$a1538-3628
001038463 0247_ $$2ISSN$$a2168-6211
001038463 0247_ $$2ISSN$$a2374-2976
001038463 0247_ $$2ISSN$$a2374-300X
001038463 0247_ $$2ISSN$$a2374-3018
001038463 0247_ $$2pmid$$a38557708
001038463 0247_ $$2WOS$$aWOS:001197556000001
001038463 037__ $$aFZJ-2025-01459
001038463 082__ $$a610
001038463 1001_ $$0P:(DE-HGF)0$$aHoermann, H.$$b0
001038463 245__ $$aAssociation of Fetal Catecholamines With Neonatal Hypoglycemia
001038463 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2024
001038463 3367_ $$2DRIVER$$aarticle
001038463 3367_ $$2DataCite$$aOutput Types/Journal article
001038463 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738322427_16008
001038463 3367_ $$2BibTeX$$aARTICLE
001038463 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001038463 3367_ $$00$$2EndNote$$aJournal Article
001038463 520__ $$aImportance: Perinatal stress and fetal growth restriction increase the risk of neonatal hypoglycemia. The underlying pathomechanism is poorly understood. In a sheep model, elevated catecholamine concentrations were found to suppress intrauterine insulin secretion, followed by hyperresponsive insulin secretion once the adrenergic stimulus subsided.Objective: To determine whether neonates with risk factors for hypoglycemia have higher catecholamine concentrations in umbilical cord blood (UCB) and/or amniotic fluid (AF) and whether catecholamines are correlated with postnatal glycemia.Design, setting, and participants: In a prospective cohort study of 328 neonates at a tertiary perinatal center from September 2020 through May 2022 in which AF and UCB were collected immediately during and after delivery, catecholamines and metanephrines were analyzed using liquid chromatography with tandem mass spectrometry. Participants received postnatal blood glucose (BG) screenings.Exposure: Risk factor for neonatal hypoglycemia.Main outcomes and measures: Comparison of catecholamine and metanephrine concentrations between at-risk neonates and control participants, and correlation of concentrations of catecholamines and metanephrines with the number and severity of postnatal hypoglycemic episodes.Results: In this study of 328 neonates (234 in the risk group: median [IQR] gestational age, 270 [261-277] days; and 94 in the control group: median [IQR] gestational age, 273 [270-278] days), growth-restricted neonates showed increased UCB median (IQR) concentrations of norepinephrine (21.10 [9.15-42.33] vs 10.88 [5.78-18.03] nmol/L; P < .001), metanephrine (0.37 [0.13-1.36] vs 0.12 [0.08-0.28] nmol/L; P < .001), and 3-methoxytyramine (0.149 [0.098-0.208] vs 0.091 [0.063-0.149] nmol/L; P = .001). Neonates with perinatal stress had increased UCB median (IQR) concentrations of norepinephrine (22.55 [8.99-131.66] vs 10.88 [5.78-18.03] nmol/L; P = .001), normetanephrine (1.75 [1.16-4.93] vs 1.25 [0.86-2.56] nmol/L; P = .004), and 3-methoxytyramine (0.120 [0.085-0.228] vs 0.091 [0.063-0.149] nmol/L; P = .008) (P < .0083 was considered statistically significant). Concentrations of UCB norepinephrine, metanephrine, and 3-methoxytyramine were negatively correlated with AF C-peptide concentration (rs = -0.212, P = .005; rs = -0.182, P = .016; and rs = -0.183, P = .016, respectively [P < .017 was considered statistically significant]). Concentrations of UCB norepinephrine, metanephrine, and 3-methoxytyramine were positively correlated with the number of hypoglycemic episodes (BG concentration of 30-45 mg/dL) (rs = 0.146, P = .01; rs = 0.151, P = .009; and rs = 0.180, P = .002, respectively). Concentrations of UCB metanephrine and 3-methoxytyramine were negatively correlated with the lowest measured BG concentration (rs = -0.149, P = .01; and rs = -0.153, P = .008, respectively).Conclusions and relevance: Neonates at risk for hypoglycemia displayed increased catecholamine and metanephrine concentrations that were correlated with postnatal hypoglycemic episodes and lower BG levels; these results are consistent with findings in a sheep model that fetal catecholamines are associated with neonatal β-cell physiology and that perinatal stress or growth restriction is associated with subsequent neonatal hyperinsulinemic hypoglycemia. Improving the pathomechanistic understanding of neonatal hypoglycemia may help to guide management of newborns at risk for hypoglycemia.
001038463 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001038463 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001038463 7001_ $$0P:(DE-HGF)0$$avan Faassen, M.$$b1
001038463 7001_ $$0P:(DE-HGF)0$$aRoeper, M.$$b2
001038463 7001_ $$0P:(DE-HGF)0$$aHagenbeck, C.$$b3
001038463 7001_ $$0P:(DE-HGF)0$$aHerebian, D.$$b4
001038463 7001_ $$0P:(DE-HGF)0$$aMuller Kobold, AC.$$b5
001038463 7001_ $$0P:(DE-Juel1)177727$$aDukart, Jürgen$$b6$$eCorresponding author
001038463 7001_ $$0P:(DE-HGF)0$$aKema, IP.$$b7
001038463 7001_ $$0P:(DE-HGF)0$$aMayatepek, E.$$b8
001038463 7001_ $$0P:(DE-HGF)0$$aMeissner, T.$$b9
001038463 7001_ $$0P:(DE-HGF)0$$aKummer, S.$$b10
001038463 773__ $$0PERI:(DE-600)2701232-3$$a10.1001/jamapediatrics.2024.0304$$gVol. 178, no. 6, p. 577 -$$n6$$p577-585$$tJAMA pediatrics$$v178$$x2168-6203$$y2024
001038463 909CO $$ooai:juser.fz-juelich.de:1038463$$pVDB
001038463 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177727$$aForschungszentrum Jülich$$b6$$kFZJ
001038463 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001038463 9141_ $$y2024
001038463 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA PEDIATR : 2022$$d2025-01-02
001038463 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJAMA PEDIATR : 2022$$d2025-01-02
001038463 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
001038463 980__ $$ajournal
001038463 980__ $$aVDB
001038463 980__ $$aI:(DE-Juel1)INM-7-20090406
001038463 980__ $$aUNRESTRICTED